Condition: Hepatocellular Carcinoma · Cirrhosis · Sponsor: Inova Health Care Services
This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.
This description comes directly from the study's public registry record.
Elahe Mollapour · 571-472-0615 · elahe.mollapour@inova.org
Keary Jane't · 571-472-0234 · keary.janet@inova.org
Always discuss trial participation with your own doctor first.
| Inova Schar Cancer Institute | Fairfax, Virginia, United States | Recruiting |
| Inova Health Care Service | Falls Church, Virginia, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06007846